Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Multi-parameter Diagnostic Blood Test (RH-VAL)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Unknown
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Validate a multi-parameter diagnostic test that combines different blood markers to identify and correctly classify patients with Alzheimer's disease (AD) compared to individuals with behavioral variant frontotemporal dementia (bvFTD, patient control) versus cognitively healthy individuals (healthy control).

Target Population/ Population Being Studied

Cognitively healthy controls, people with AD, and people with Frontotemporal dementia

Length of Current Trial
12 months
Number of Trial Participants

700

Estimated Trial Completion
September 2018
What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

Raman Health Technologies, S.L.

“Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease (RH-VAL).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT02409030?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=3&rank=29